Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China
· Delayed Price · Currency is CNY 36.26
-0.01 (-0.03%)
Apr 29, 2026, 3:00 PM CST
SHA:603590 Revenue
Beijing Konruns Pharmaceutical had revenue of 214.87M CNY in the quarter ending March 31, 2026, with 1.35% growth. This brings the company's revenue in the last twelve months to 917.99M, up 9.52% year-over-year. In the year 2025, Beijing Konruns Pharmaceutical had annual revenue of 915.12M with 10.87% growth.
Revenue (ttm)
917.99M
Revenue Growth
+9.52%
P/S Ratio
6.28
Revenue / Employee
1.37M
Employees
668
Market Cap
5.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 915.12M | 89.73M | 10.87% |
| Dec 31, 2024 | 825.40M | -94.61M | -10.28% |
| Dec 31, 2023 | 920.01M | 53.29M | 6.15% |
| Dec 31, 2022 | 866.73M | 56.94M | 7.03% |
| Dec 31, 2021 | 809.78M | 1.14M | 0.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaResources (Shanghai) | 691.21M |
| Shenzhen Weiguang Biological Products | 1.26B |
| Kexing Biopharm | 1.53B |
| Novogene | 2.26B |
| Lifecome Biochemistry | 502.95M |
| Shouyao Holdings (Beijing) Co., LTD. | 34.67M |
| R&G PharmaStudies | 896.26M |
| Wuhan Hvsen Biotechnology | 1.74B |